LONDON, UK - SkyePharma PLC (LSE: SKP) today announces the launch of flutiform® in Germany by Mundipharma GmbH, an affiliate of the Group's development, marketing and distribution partner, Mundipharma International Corporation Limited ("Mundipharma").
flutiform® was approved for the treatment of asthma maintenance therapy in Germany by its regulatory authority, Bundesinstitut für Arzneimittel und Medizinprodukte (BfARM), as announced on 17 July 2012.
Following the launch offlutiform® in Germany, a milestone of €4.0 million is due to SkyePharma. Half of this amount will be allocated as a prepayment of the Paul Capital Note.
As announced on 3 July 2012, the European Commission ("EC") adopted a decision in favour of granting marketing authorisations for flutiform®. This decision is binding on the 21 member states in the decentralised procedure ("DCP"). To date, in addition to Germany, marketing authorisations of flutiform® have also been granted in the UK, Austria, Cyprus, the Netherlands, Norway, the Slovak Republic and Sweden. Mundipharma aims to launch flutiform® in each of these countries through its network of independent associated companies as soon as possible.
Peter Grant, Chief Executive Officer of SkyePharma, commented:
"We are extremely pleased that flutiform is now commercially available to both patients and doctors in Germany for the treatment of asthma. For the first time in Europe there is now a product that combines two of the most effective asthma medications available, offering patients a new fast-acting combination treatment in a modern and easy to use inhaler. We look forward to the continued roll-out of flutiform across Europe by our partner Mundipharma."
A novel combination, flutiform® combines fluticasone propionate (fluticasone), an inhaled corticosteroid (ICS), and formoterol fumarate (formoterol), a long-acting β2-agonist (LABA) in a single aerosol inhaler incorporating SkyePharma's proprietary SkyeDry™ technology. flutiform® will be indicated for the regular treatment of asthma in patients aged 12 years and over (50/5µg and 125/5µg strengths) and in adults (250/10µg strength) whose symptoms are not adequately controlled on an ICS and an as-required inhaled short-acting β2-agonist (SABA), and in those patients who are already receiving treatment with both an ICS and LABA.1
For further information please contact:
Peter Grant, Chief Executive Officer
+44 207 881 0524
Jonathan Birt/Julia Phillips/Susan Stuart
+44 207 831 3113
Clinical evidence behind flutiform®
The SkyePharma Group commenced development of flutiform® in 2004 and carried out a substantial part of the development of the product including all the pre-clinical and chemistry, manufacturing and control work as well as a substantial part of the clinical trials. In 2006 the Group appointed Mundipharma International Corporation Limited as the development partner and authorised distributor of flutiform® for Europe and most other territories outside Japan and the Americas.
The European Commission decision was based on a regulatory package of nine Phase I/II studies and nine Phase III trials, which were conducted in a patient population of approximately 5,000, of whom 1,900 received flutiform®.
The Phase III clinical trials have demonstrated the efficacy and tolerability profile of flutiform® across a range of asthma severities and in comparison with two currently available combination therapies for asthma (fluticasone/salmeterol and budesonide/formoterol).1,2,3,4
Phase III clinical trial data (8-12 weeks) demonstrated that the new combination:
- is more effective in improving asthma symptom scores, including an improvement in the percentage of symptom-free days and awakening-free nights, compared with a similar dose of fluticasone alone4
- provides similar improvements in lung function parameters, control of asthma symptoms and similar level of exacerbations compared to its individual components administered concurrently via separate inhalers4
- has a more rapid onset of bronchodilatory action than the fluticasone/salmeterol combination as defined by the first time point post-dose at which FEV1 was at least 12 percent greater than the pre-dose value. The superiority of fluticasone/formoterol combination (100/10 or 250/10 μg b.i.d.) compared to the fluticasone/salmeterol combination (100/50 or 250/50 μg b.i.d.) was shown over a 12-week study period (HR 1.64)3
- has a tolerability profile similar to that of its individual components administered concurrently via separate inhalers4
For prescribing and labelling information refer to www.flutiform.info.
Using its multiple drug delivery technologies and expertise, SkyePharma creates enhanced versions of pharmaceutical products. The Group receives revenues from thirteen approved products in the areas of inhalation, oral, topical and injectable delivery as well as generating income from the development of further products and technology licenses. The Group's products are marketed throughout the world by leading pharmaceutical companies. For more information, visit www.skyepharma.com.
The Mundipharma independent associated companies have become leaders in pain management, and are building a growing presence in the oncology, rheumatoid arthritis and respiratory markets. Through innovation and acquisition, the Mundipharma mission is to deliver cutting-edge treatment solutions that meet the pressing needs of healthcare professionals and patients. For more information: www.mundipharma.com.
1flutiform® Summary of Product Characteristics
2Bodzenta-Lukaszyk A, R Buhl, et al. Eur Respir J 2011a;38:153s
3 Bodzenta-Lukaszyk A, Dymek A et al. BMC Pulm Med J. 2011;11:28
4 Bodzenta-Lukaszyk A, Pulka et al. Respir Med J. 2011;105(5):674-82